CUMHUR ARTUK, Hanefi GÜL CEM, Ömer COŞKUN

Human papilloma virüs (hpv) aşılamasına güncel bakış

Yüksek riskli Human Papillomavirüs (HPV) tiplerinin neden olduğu uzun süreli viral enefeksiyonlar serviks kanserinin nedenidir. Aynı tipler anal kanserlerin de etkenidir. Serviks kanseri, tüm dünyada kadın kanserleri içerisinde meme ve kolorektal kanserlerden sonra üçüncü sıklıkta yer almaktadır. Mortalite oranlarına göre kadın kanserleri içinde dördüncü sırada yer almaktadır. İki tip HPV’ye karşı aşı geliştirilmiştir. Biri Kuadrivalan aşı (GardasilTM), diğeri Bivalan aşı (CervarixTM)’dır. Bu yazıda HPV enfeksiyonları, rutin HPV immünizasyonu önerileri, özel hasta popülâsyonlarında aşılama, aşının maliyet etkinliği ve aşı güvenliği ile ilgili konular ele alınacaktır.

[Overview of current humman papilloma virus (hpv) vaccination]

Persistent viral infection with high-risk human papillomavirus (HPV) genotypes causes virtually all cancer of the cervix. The same HPV genotypes (“types”) also cause cases of anal cancer. Cervical cancer is the third most frequent cancer in women worldwide after breast and colorectal cancers. It ranks fourth of women’s cancers according to the mortality ratio. Two vaccines have been developed against HPV infection; one is a quadrivalent vaccine (GardasilTM) and the other is a bivalent vaccine (CervarixTM). This topic will cover issues related to HPV infections, routine HPV immunization recommendations, vaccination in special patient populations, the cost-effectiveness of HPV vaccination, and vaccine safety.

PDF

___

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12): 2893-2917.
2. American Cancer Society (ACS). Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010.
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19.
4. Munoz N, Bosch FX, de Sanjosé et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med. 2003; 348(6): 518-27.
5. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005; 6: 204.
6. Woodman CBJ, Collins SI, Young LS. The nature history of cervical HPV infection: unresolved issues. Nat Rev Canad. 2007; 7: 11-22.
7. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis. 2001; 183: 1554–64.
8. Pakin DM, Bray F. Chapter 2: the burden of HPV related cancer. Vaccine 2006; 24 (Suppl 3): p.11- 25.
9. Vanchiere JA, Demmler GJ: Human Polyomaviruses and Papillomaviruses, “Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (eds): Textbook of Pediatric Infectious Diseases. 5th edition. Saunders, Philadelphia; 2004. p. 1809-31.
10. Sellors JW, Karwalajtys TL, Kaczorowski J, et al. Incidence, clearance and predictors of human papillomavirus infection in women. Can Med Assoc J. 2003; 168: 421-5.
11. Munoz N, Castellsague X, Gonzales AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006; 24: 1-10.
12. Dunne EF, Unger ER, Sternberg M, et al: Prevalence of HPV infection among females in the United States, JAMA. 2007; 297(8): 813-9.
13. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006; 24: 16-22.
14. Cervarix™--a second HPV vaccine. Med Lett Drugs Ther. 2010; 52(1338): 37-8.
15. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010; 10: 845.
16. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2010. Ann Intern Med. 2010; 152: 36.
17. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix™) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR. Morb Mortal Wkly Rep. 2010; 59: 626.
18. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recomm Rep. 2007; 56: 1.
19. National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recomm Rep. 2011; 60: 1.
20. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007; 57: 7.
21. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent highgrade cervical lesions. N Engl J Med. 2007; 356: 1915.
22. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2009. Ann Intern Med 2009; 150:40.
23. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010; 202: 1246.
24. Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr. 2010; 55: 197.
25. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer. 2009; 124: 2375.
26. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003; 36: 1397.
27. Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 2008; 113: 2892.
28. U.S. Food and Drug Administration. Male indication for Gardasil™. 2009. www.fda.gov/downloads/AdvisoryCommittees/Co mmitteesMeetingMaterials/BloodVaccinesandOthe rBiologics/VaccinesandRelatedBiologicalProducts AdvisoryCommittee/UCM181361.pdf (Accessed on November 30, 2009).
29. HPV Vaccine Recommendations. Commite on Infectious Disease. Pediatrics. 2012; 129: 602- 605.
30. Petäjä T, Keränen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health. 2009; 44: 33.
31. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007; 26: 201.
32. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011; 364: 401.
33. Palefsky J, Male Quadrivalent HPV Vaccine Efficacy Trial Team. Quadrivalent HPV vaccine efficacy against anal intraepithelial neoplasia in men having sex with men. International Papillomavirus Conference, Montreal, Canada Abstract #456 (Accessed on September 24, 2010).
34. Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil™) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR. Morb Mortal Wkly Rep. 2010; 59: 630.
35. Neuzil KM, Canh do G, Thiem VD, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA. 2011; 305: 1424.
36. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003; 9: 37.
37. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96: 604.
38. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003; 290: 781.
39. Chesson, HW, et al. Cost effectiveness models of HPV vaccines. May 9, 2006 - 2006 National STD Prevention Conference.
40. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008; 359: 821.
41. Clinical management guidelines for the Obstetrician-Gynecologists. Cervical cytology screening. ACOG Practice Bulletin. 2009; 109. (Replaces Practice Bulletin Number 45, August 2003 and Committee Opinion Number 431, May 2009)
42. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003; 9: 37.
43. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96: 604.
44. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003; 290: 781.
45. Chesson, HW, et al. Cost effectiveness models of HPV vaccines. May 9, 2006 - 2006 National STD Prevention Conference.